Investment Thesis
Brainstorm Cell Therapeutics faces severe financial distress with negative stockholders' equity of -7.7M, liabilities exceeding assets by 7.7x, and no revenue generation. The company is burning cash at an unsustainable rate (-6.2M operating cash flow) with minimal liquidity (5.0K cash) and a critically low current ratio of 0.06x, indicating imminent solvency concerns.
Strengths
- Company has not yet filed for bankruptcy, indicating some ongoing operations
- EPS improved 61.5% year-over-year, though still deeply negative
- No long-term debt obligations that could accelerate financial distress
Risks
- Negative stockholders' equity (-7.7M) indicates liabilities exceed assets; company is technically insolvent
- Zero revenue with -7.9M net loss and -6.2M operating cash burn; business model not generating income
- Critical liquidity crisis: only 5.0K cash on hand with 9.1M total liabilities and current ratio of 0.06x
- Negative ROA of -570.5% demonstrates severe asset inefficiency and value destruction
- No insider buying activity in last 90 days suggests lack of management confidence
- Dependency on external financing or capital raises for survival
Key Metrics to Watch
- Cash balance and runway to next financing event
- Quarterly cash burn rate trends and path to profitability/revenue generation
- Changes in stockholders' equity and potential debt restructuring or dilutive equity raises
- Operating cash flow improvements or further deterioration
Financial Metrics
Revenue
N/A
Net Income
-7.9M
EPS (Diluted)
$-0.91
Free Cash Flow
-6.3M
Total Assets
1.4M
Cash
5.0K
Profitability Ratios
Gross Margin
N/A
Operating Margin
N/A
Net Margin
N/A
ROE
N/A
ROA
-570.5%
FCF Margin
N/A
Balance Sheet & Liquidity
Current Ratio
0.06x
Quick Ratio
0.06x
Debt/Equity
N/A
Debt/Assets
657.5%
Interest Coverage
-3.14x
Long-term Debt
N/A
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-03-20T19:28:12.408097 |
Data as of: 2025-09-30 |
Powered by Claude AI